Physician profile
Fredric Gross
NPI 1184629271
$7,113.24
in general payments reported to CMS, 2019-2025
27 companies · $615 in 2025
The $615 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $881 · 2020: $635 · 2021: $1,572 · 2022: $1,495 · 2023: $1,441 · 2024: $474 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.09 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,473.52 | 2019-2025 | Clareon, Centurion, Argos |
| Abbvie INC. | $1,347.47 | 2022-2025 | |
| Allergan, INC. | $969.92 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $664.86 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $443.83 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $345.99 | 2022-2023 | Vyzulta, Miebo, Lotemax Sm |
| Aerie Pharmaceuticals, INC. | $317.36 | 2019-2021 | |
| New World Medical,INC. | $274.42 | 2023 | |
| Kala Pharmaceuticals, INC. | $198.85 | 2019-2021 | |
| Ocular Therapeutix, INC. | $189.11 | 2021-2024 | Dextenza |
| Biotissue Holdings INC. | $141.98 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $125.18 | 2022-2023 | Cequa, Xelpros |
| Mallinckrodt Hospital Products INC. | $92.95 | 2021-2024 | Acthar |
| Sight Sciences, INC. | $81.05 | 2023 | Sion Surgical Instrument, Omni Surgical System |
| Eyevance Pharmaceuticals LLC | $69.34 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iridex Corporation | $51.72 | 2019-2022 | |
| Lensar, INC. | $41.90 | 2024-2025 | Lensar Laser System |
| Oyster Point Pharma, INC. | $40.14 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $38.08 | 2019-2024 | Idose |
| Thea Pharma INC. | $37.95 | 2024-2025 | Iyuzeh |
| Omeros Corporation | $34.93 | 2019-2020 | |
| Shire North American Group INC | $32.67 | 2019 | |
| Horizon Therapeutics Plc | $32.05 | 2019-2023 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $27.74 | 2024 | Xdemvy |
| Amgen INC. | $15.18 | 2025 | Uplizna |
| Oasis Medical, INC. | $12.69 | 2019 | |
| Carl Zeiss Meditec, INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fredric Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.